Yingpai Pharmaceutical-B (07630) released interim results with revenue of 105 million yuan, a year-on-year increase of 316.8%

According to the Zhitong Finance App, Yingpai Pharmaceutical-B (07630) announced interim results for the six months ended June 30, 2026. The group's revenue was RMB 105 million, up 316.8% year on year; net loss was RMB 90.81 million, narrowing 29.5% year on year; and R&D expenditure was 97.637 million yuan, up 13.1% year on year.

As of the date of this announcement, the company's R&D pipeline includes 1 commercial-stage drug, 4 clinical-stage drugs, and 7 pre-IND drugs, including small molecule inhibitors covering key synthetic lethal targets such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2, and emerging therapies such as dual-load ADC targeting CEACAM5 and KAT6A-specific PROTAC.